We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBiome Tech Regulatory News (BIOM)

Share Price Information for Biome Tech (BIOM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 77.50
Bid: 70.00
Ask: 85.00
Change: 0.00 (0.00%)
Spread: 15.00 (21.429%)
Open: 77.50
High: 0.00
Low: 0.00
Prev. Close: 77.50
BIOM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Grant funding from Innovate UK

6 Dec 2018 07:00

RNS Number : 5952J
Biome Technologies PLC
06 December 2018
 

 

6 December 2018

 

Biome Technologies plc

 

("Biome", "the Company" or "the Group")

 

 

Biome Technologies plc, the leading bioplastics and radio frequency technology business, is pleased to announce that it has been awarded a further £0.6 million of grant funding from Innovate UK to support a project focused on pilot-scale production of a novel bioplastic building block.

 

Over the last five years, Biome Technologies has led a £6 million development programme to bring a range of novel highly functional bio-based and biodegradable polymers to market using industrial biotechnology techniques. This programme currently involves seven universities, some 25 scientists and engineers and other partners.

 

Earlier in 2018, the Company reported that the technical feasibility of a number of these potential polymers had been ascertained and that work was now to be focused on establishing the viability of production and commercial scale-up. Following extensive techno-economic analysis this project, one of three key elements of our work in this area, will focus on the scale-up of of PDCA (2,5-pyridinedicarboxylic acid) from bio-based intermediates that can be obtained from the lignin breakdown pathway.

 

This two-year, £0.8 million project in collaboration with the University of Nottingham will use a robust, metabolically diverse organism (Cupriavidus necator) in a contained environment to produce PDCA at pilot-scale. The work uses advanced synthetic biology techniques and state-of-the-art processing for the eventual production of highly biodegradable, compostable and recyclable bioplastic polymers suitable for flexible packaging applications.

 

Biome Technologies CEO Paul Mines commented:

 

"The UK government has set a target of eliminating all avoidable plastic waste by 2042. Bioplastics will play a crucial role in achieving this target by reducing waste. However, current bioplastic technology is limited by price and performance in some applications. Our development programme is intended to change that position by preparing a new generation of polymers with improved functionality."

 

The funding, provided by UK Research and Innovation and delivered by Innovate UK, was awarded as part of a £20 million Open Competition to deliver game changing or disruptive innovations with significant potential for impact on the UK economy.

 

The UK Government's Industrial Strategy sets out 4 Grand Challenges, including Clean Growth, to put the UK at the forefront of the industries of the future. Exemplifying the focus on renewable materials, on 5 December 2018, up to £60 million of new public funding was announced for the Smart Sustainable Plastic Packaging Challenge, through the Industrial Strategy Challenge fund. Illustrating economic potential of such products, a recent report by bioeconomy consultants NNFCC found that plastics made from plants instead of oil, many of which are biodegradable - could create 34,000 jobs and contribute £1.92 billion to the UK economy in the next decade.

 

More information about the Group's work in this area can be found at www.biomebioplastics.com/industrial-biotechnology.

 

  

- Ends -

 

 

 

For further information please contact: Biome Technologies plc

 

Paul Mines, Chief Executive Officer

Declan Brown, Group Finance Director

www.biometechnologiesplc.com

Tel: +44 (0) 2380 867 100

 

Allenby Capital

David Hart/Alex Brearley (Nominated Adviser)

Kelly Gardiner (Broker)

www.allenbycapital.com

Tel: +44 (0) 20 3328 5656

 

 

 

 

About Biome

Biome Technologies plc is an AIM listed, growth-orientated, commercially driven technology group. Our strategy is founded on building market-leading positions based on patented technology and serving international customers in valuable market sectors. We have chosen to do this by developing products in application areas where the value-added pricing can be justified and that are not reliant on government legislation. These products are driven by customer requirements and are compatible with existing manufacturing processes. They are market rather than technology-led.

 

The Group comprises two divisions, Biome Bioplastics Limited and Stanelco RF Technologies Limited. Biome Bioplastics is a leading developer of highly-functional, bio-based and biodegradable plastics. The company's mission is to produce bioplastics that challenge the dominance of oil-based polymers. Stanelco RF Technologies designs, builds and services advanced radio frequency (RF) systems. Dielectric and induction heating products are at the core of a product offering that ranges from portable sealing devices to large furnaces for the fibre optics markets.

 

In 2018, the Board has adopted the following three high level KPIs for the next three years to continue its ambitious momentum:

· Compound revenue growth of 25% per annum across the Group and 40% compound revenue growth in the Bioplastics division

· Diversify the Group's turnover by product and market to ensure that no one product or end customer contributes more than 15% of revenues by 2020

· Increase investment in the Group's next generation of products by spending significantly more per annum on average than the £0.3m per annum average spend over the previous strategic objective cycle

 

www.biometechnologiesplc.com

www.biomebioplastics.com and www.thinkbioplastic.com 

www.stanelcorftechnologies.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NRAEAPASEEEPFFF
Date   Source Headline
16th Oct 20063:17 pmRNSNotifiable Interest
12th Oct 200612:35 pmRNSDoc re. Posting of Prospectus
11th Oct 20061:09 pmRNSNotifiable Interest
9th Oct 200611:13 amRNSProposed Placing & Open Offer
5th Oct 200610:25 amRNSFinancing Update
3rd Oct 200612:56 pmRNSStatement re. Press Comment
2nd Oct 20064:41 pmRNSSecond Price Monitoring Extn
2nd Oct 20064:35 pmRNSPrice Monitoring Extension
8th Sep 20067:01 amRNSTrading Statement
17th Aug 20067:44 amRNSTrading Statement
16th Aug 20065:52 pmRNSAdditional Listing - AMEND
14th Aug 200611:55 amRNSAdditional Listing
10th Aug 200612:25 pmRNSRe Contract
14th Jul 20067:56 amRNSInterim Results - Replacement
14th Jul 20067:00 amRNSInterim Results
2nd Jun 200611:26 amRNSNew Ord Share Placing-Amendmt
2nd Jun 20068:45 amRNSNew Ordinary Share Placing
25th May 20067:02 amRNSWrap 100 FDA approval
16th May 200610:43 amRNSAdditional Listing
15th May 20067:01 amRNSAppointment of Adviser
3rd May 20061:05 pmRNSNotifiable Interest
2nd May 20064:58 pmRNSResult of AGM
2nd May 20062:00 pmRNSAGM Statement
10th Apr 20063:12 pmRNSAnnual Report and Accounts
7th Apr 20062:46 pmRNSAdditional Listing
13th Mar 20067:02 amRNSDirectorate Change
28th Feb 20067:02 amRNSPreliminary Results
24th Feb 20067:02 amRNSCooperation with Wal-Mart
14th Feb 20069:07 amRNSAdditional Listing
14th Feb 20067:00 amRNSUS FDA approval for Starpol
9th Feb 200610:42 amRNSIsraCaps new licence terms
9th Feb 20067:02 amRNSRe: BioProgress plc
16th Dec 20057:01 amRNSFunding for R&D facility
16th Dec 20057:01 amRNSPre Close Update
14th Dec 20057:01 amRNSLandmark deal with Perseco
8th Dec 200510:25 amRNSShare Listing Application
30th Nov 20055:40 pmRNSDirectorate Change
28th Nov 20059:24 amRNSBoard Changes
8th Nov 20057:01 amRNSPatent sale process update
3rd Nov 20054:47 pmRNSExercise of Options
1st Nov 20057:02 amRNSChange of Adviser
12th Oct 20057:00 amRNSApproval of Starpol
3rd Oct 20057:00 amRNSPatent Disposal & Update
22nd Sep 20057:02 amRNSRe Agreement
12th Sep 20057:03 amRNSDevelopment of capsule
5th Sep 20057:03 amRNSRe: Completion
30th Aug 20053:30 pmRNSDoc re. Result of EGM
30th Aug 200511:08 amRNSEGM Statement
30th Aug 20057:03 amRNSRe Agreement
5th Aug 200511:15 amRNSRe posting of circular

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.